Paradigm4, 54gene collaborate on African clinical data
With fewer than 3% of analyzed genomes currently coming from Africans, the companies are looking to increase access to and understanding of patient data.
With fewer than 3% of analyzed genomes currently coming from Africans, the companies are looking to increase access to and understanding of patient data.
While the field is decades old, according to one specialist, more and more industry professionals are noting its diagnostic and treatment potential.
While the change signifies the life-sciences solutions firm’s commitment to help customers and patients, day-to-day functions will remain much the same.